5.0T人体全身磁共振系统uMR Jupiter

Search documents
中国跻身全球第二大生物药市场
Zhong Guo Chan Ye Jing Ji Xin Xi Wang· 2025-09-29 00:42
Core Insights - China's bio-economy is showing a positive trend, with significant advancements in CAR-T cell therapy, original drug production, and brain-machine interface medical devices, positioning the country as the second-largest biopharmaceutical market globally [1][2] Industry Overview - The global bio-manufacturing industry is receiving heightened attention from major economies, with increased funding for genetic and cell engineering research, biomass utilization, and bio-based product development [2] - The number of CAR-T clinical research centers worldwide has grown to 2069 in 2024, a 60% increase from 1297 in 2020, with China hosting 388 centers, ranking second globally [2] - China has achieved a record high in the proportion of self-developed new drugs, with 93 new drugs approved by the National Medical Products Administration in 2024, marking a five-year peak [2] Research and Development - In 2024, China published over 20,000 SCI papers in the medical equipment field, leading globally in research output [3] - The bio-economy in China is characterized by a robust industrial foundation, with significant growth in the pharmaceutical and chemical sectors driven by advancements in synthetic biology and high-throughput screening technologies [3] Industry Transformation - The bio-industry is transitioning from "quantitative accumulation" to "qualitative leap," focusing on core technology breakthroughs, product quality upgrades, and enhancing supply chain resilience [4] - Notable innovations include the approval of the world's first "rice-derived" human serum albumin injection and the launch of the world's first 5.0T whole-body MRI system [4] Future Prospects - Innovations in synthetic biology and gene editing are driving rapid growth in bio-manufacturing, outpacing GDP growth, and positioning the bio-economy as a crucial sector in the future global economy [5]
科技赋能健康生活
Jing Ji Ri Bao· 2025-09-25 22:10
Core Viewpoint - The 2025 China International Service Trade Fair features a health and hygiene services section that showcases innovations in the health industry, highlighting the strong momentum of health industry upgrades in China [1]. Group 1: Health Technology Innovations - The "优促计划" theme exhibition, organized by the Beijing Municipal Health Commission, showcases over 50 medical technology achievements, making it one of the most technologically advanced areas of the health services exhibition [2]. - A handheld smart fundus camera demonstrated at the exhibition can quickly capture eye images and identify over 20 types of eye abnormalities using AI, aiding in early detection of eye diseases [2]. - The intelligent refractive screening device and electronic vision chart for children provide efficient eye health screening solutions, developed through collaboration among various institutions, addressing the needs of different age groups [3][4]. Group 2: Project Acceleration and Commercialization - The "优促计划" aims to accelerate the commercialization of medical technology innovations, with a project reserve of 1,371 and a pool of nearly 10,000 experts, resulting in 69 projects being commercialized with a total contract value of 555 million yuan [4]. - The establishment of a national AI application pilot base in the medical field was announced, featuring 14 common service capabilities and 31 AI application scenarios to enhance the health industry [5]. Group 3: AI and Smart Health Solutions - The AI virtual doctor "融融" provides health consultations and triage suggestions, showcasing the integration of AI in patient care and decision-making processes [5]. - A retinal disease and chronic disease warning system, developed by Beijing Tongren Hospital and Eagle Eye Technology, uses AI to assess overall vascular health through retinal imaging, achieving commercial success in multiple community health centers [6]. Group 4: Advanced Medical Equipment - Siemens introduced the world's first photon-counting CT, which has been installed in over 20 hospitals across 15 provinces, with more than 180,000 patient scans completed [7]. - The exhibition featured various high-end medical devices and AI solutions, including the world's first 5.0T whole-body MRI system and an AI catheter shaping robot, showcasing significant advancements in medical technology [7]. Group 5: Innovative Service Models - Tianjin Pengruili Hospital presented a comprehensive service model that integrates hospital, rehabilitation, and wellness services, demonstrating a multi-faceted approach to healthcare delivery [8]. - The ongoing development of AI and cloud computing technologies is expected to accelerate the transformation of the healthcare industry towards digitalization and personalization, enhancing consumer experiences [8].
《中国生物经济发展报告2025》发布,中国跻身全球第二大生物药市场
Zheng Quan Shi Bao Wang· 2025-09-04 14:01
Group 1 - The 17th China Bio-Industry Conference highlighted that China has become the second-largest biopharmaceutical market globally, meeting domestic demand while gradually participating in international market competition [1] - The report indicates that China is in a leading position in areas such as biopharmaceuticals under research, brain-machine interfaces, and high-precision digital slicing [1] - The global focus on biomanufacturing and circular economy strategies is increasing, with significant funding for gene and cell engineering research, biomass utilization, and the development of bioproducts [1] Group 2 - In 2024, China approved 93 new drugs, the highest in five years, and ranks second globally in the number of drugs under research [2] - Four Chinese companies made it to the top 25 global pharmaceutical companies in terms of R&D pipeline scale, marking a historic achievement [2] - China leads the world in the number of SCI papers published in medical equipment, with over 20,000 papers in 2024, showcasing strong research resources and innovation capabilities [2] Group 3 - The National Development and Reform Commission reported that China has established 23 biomanufacturing bases, leading in biotechnology patent applications and R&D personnel [2] - The biopharmaceutical industry in China ranks second globally, with innovative drugs, research pipelines, and newly approved drugs accounting for over 30% of the global total [2] - The value of biobased materials and chemicals has surpassed 1 trillion yuan, with the contribution of the bio-economy to GDP exceeding 7% [2] Group 4 - The conference featured over 200 renowned institutions and companies, showcasing more than 1,000 products, including several global firsts [2] - Notable innovations included a multimodal sensing system for brain rehabilitation and a world-first 5.0T whole-body MRI system [3] - The collaboration between China and Cuba in biotechnology was highlighted as a successful partnership, with joint research and production benefiting both nations [3]